10 September 2024 · 1 min read
$120M Alert: Another significant funding round in AI-driven drug discovery, this time with Lilly...
Another significant $120M funding round has landed in AI-driven drug discovery, this time with Lilly leading alongside Nvidia and key VC funds. I'm optimistic that we could be witnessing the birth of the next Amgen, Genentech, or Biogen — powered by AI.
Author
Last updated
6 May 2026
$120M Alert: Another significant funding round in AI-driven drug discovery, this time with Lilly leading the way!
The surge in investments for AI-enabled biotech and techbio companies continues strong. Recent rounds include Formation Bio, Xaira Therapeutics, and now, Lilly - alongside Nvidia and key VC funds - investing $120M into a company focused on GPCR targets, leveraging a fully virtual screening approach.
Despite challenges faced by companies like Recursion, I believe this is just the beginning. We might be witnessing the birth of the next Amgen, Genentech, or Biogen - the giants that emerged from the molecular biology revolution. Could AI be the driving force behind the next wave of biopharma innovation? I'm optimistic.